Genotoxicity, carcinogenicity and acid-suppressing medications

Area of Science:

• Pharmacology
• Toxicology
• Genetics

Background:

• Increasingly potent acid-suppressing medications raise safety concerns regarding carcinogenicity.
• Genotoxicity, the alteration of cellular genomic information by chemical agents, is a key area of investigation.
• Carcinogenesis, the process by which normal cells become cancerous, is evaluated in relation to these drugs.

Purpose of the Study:

• To review current concepts and procedures for assessing genotoxicity and carcinogenesis.
• To evaluate the safety of therapeutically relevant acid-suppressing medications concerning their carcinogenic potential.
• To discuss the effects of prolonged drug administration, including serum gastrin level alterations and tumor promotion.

Main Methods:

• Description and discussion of techniques for determining in vitro mutagenicity.
• Assessment of in vitro and in vivo DNA damage and repair mechanisms.
• Evaluation of in vitro and in vivo chromosomal damage.
• Analysis of chronically dosed animal tumorigenesis development.

Main Results:

• Observations from applied genotoxicity and carcinogenesis procedures are discussed.
• Evaluation of reports on potential genotoxic and carcinogenic hazards of cimetidine, ranitidine, and omeprazole.
• Information on prolonged administration effects, serum gastrin alterations, and tumor promotion potential is presented.

Conclusions:

• The review provides an evaluation of the genotoxic and carcinogenic risks associated with commonly used acid-suppressing medications.
• Understanding these risks is crucial for informed clinical practice and patient safety.
• Further research may be warranted to fully elucidate long-term safety profiles.